沙库巴曲缬沙坦钠治疗慢性心力衰竭的效果(1)
[摘要]目的 探討沙库巴曲缬沙坦钠治疗慢性心力衰竭的效果。方法 选取2017年1月～2019年1月我院收治的180例慢性心力衰竭患者作为研究对象，按照随机数字表法将其分为对照组和研究组，每组各90例。对照组使用缬沙坦胶囊治疗，研究组使用沙库巴曲缬沙坦钠治疗。比较两组的临床疗效、血浆N端前脑钠肽(NT-proBNP)和运动耐量水平变化。结果 研究组的治疗总有效率高于对照组，差异有统计学意义(P<0.05)。治疗后，研究组的血浆NT-proBNP水平低于对照组，差异有统计学意义(P<0.05)。治疗后，两组的血浆NT-proBNP水平低于治疗前，差异有统计学意义(P<0.05)。治疗后，研究组的6 min步行距离长于对照组，血氧饱和度(SpO2)水平高于对照组，差异有统计学意义(P<0.05)。治疗后，两组的6 min步行距离均长于治疗前，SpO2水平均高于治疗前，差异有统计学意义(P<0.05)。结论 采用沙库巴曲缬沙坦钠治疗慢性心力衰竭患者，不仅具有较好的临床效果，还可以有效提高患者的运动耐量，降低患者的血浆NT-proBNP水平，值得在临床上广泛使用。
[关键词]沙库巴曲缬沙坦钠;慢性心力衰竭;N端前脑钠肽水平;运动耐量
[中图分类号] R541.6 [文献标识码] A [文章编号] 1674-4721(2020)1(c)-0091-03
[Abstract] Objective To investigate the effect of Sharkurba Trivalsartan Sodium in the treatment of chronic heart failure. Methods A total of 180 cases of patients with chronic heart failure who received treatment in our hospital from January 2017 to January 2019 were selected as subjects， they were divided into control group and study group according to the random number table method， with 90 cases in each group. The control group was treated with Valsartan Capsules， and the study group was treated with Shakurba Triv alsartan Sodium. The clinical effect， the changes of plasma N-terminal frontal brain natriuretic peptide (NT-pro BNP) and exercise tolerance levels were compared between the two groups. Results The total effective rate in the study group was higher than that in the control group， the difference was statistically significant(P<0.05). After treatment， the plasma NT-pro BNP level in the study group was lower than that in the control group， the difference was statistically significant (P<0.05). After treatment， the plasma NT-pro BNP level of the two groups was lower than that before treatment， the difference was statistically significant (P<0.05). After treatment， the 6 min walking distance of the study group was longer than that of the control group， and the blood oxygen saturation (SpO2) level was higher than that of the control group， with statistically significant differences (P<0.05). After treatment， the 6 min walking distance of both groups was longer than that before treatment， and the SpO2 level was higher than that before treatment， with statistically significant differences (P<0.05). Conclusion The use of Shakurba Travalsartan Sodium in the treatment of chronic heart failure patients not only has a high clinical efficacy， but also can effectively improve the exercise tolerance of patients and reduce the level of plasma NT-pro BNP ， which is worthy of widely use in clinical., 百拇医药(李文波)
[关键词]沙库巴曲缬沙坦钠;慢性心力衰竭;N端前脑钠肽水平;运动耐量
[中图分类号] R541.6 [文献标识码] A [文章编号] 1674-4721(2020)1(c)-0091-03
[Abstract] Objective To investigate the effect of Sharkurba Trivalsartan Sodium in the treatment of chronic heart failure. Methods A total of 180 cases of patients with chronic heart failure who received treatment in our hospital from January 2017 to January 2019 were selected as subjects， they were divided into control group and study group according to the random number table method， with 90 cases in each group. The control group was treated with Valsartan Capsules， and the study group was treated with Shakurba Triv alsartan Sodium. The clinical effect， the changes of plasma N-terminal frontal brain natriuretic peptide (NT-pro BNP) and exercise tolerance levels were compared between the two groups. Results The total effective rate in the study group was higher than that in the control group， the difference was statistically significant(P<0.05). After treatment， the plasma NT-pro BNP level in the study group was lower than that in the control group， the difference was statistically significant (P<0.05). After treatment， the plasma NT-pro BNP level of the two groups was lower than that before treatment， the difference was statistically significant (P<0.05). After treatment， the 6 min walking distance of the study group was longer than that of the control group， and the blood oxygen saturation (SpO2) level was higher than that of the control group， with statistically significant differences (P<0.05). After treatment， the 6 min walking distance of both groups was longer than that before treatment， and the SpO2 level was higher than that before treatment， with statistically significant differences (P<0.05). Conclusion The use of Shakurba Travalsartan Sodium in the treatment of chronic heart failure patients not only has a high clinical efficacy， but also can effectively improve the exercise tolerance of patients and reduce the level of plasma NT-pro BNP ， which is worthy of widely use in clinical., 百拇医药(李文波)
参见：首页 > 医疗版 > 疾病专题 > 心血管科 > 心力衰竭 > 慢性心力衰竭